Crystalline drug form

   
   

The present invention relates to a crystalline form of 6-[(2,2-diphenylethyl)amino]-9-(N-ethyl-.beta.-D-ribofuranosyluronamide)-- N-(2-{N'-[1-(2-pyridyl)-4-piperidyl]ureido}ethyl)-9H-purine-2-carboxamide and to a process for the preparation of, compositions containing and the uses of such a crystalline form.

La présente invention concerne une forme cristalline d'6-[(2,2-diphenylethyl)amino]-9-(N-éthyles-.beta.-D-ribofuranosyluronamide) -- N-(2-{N'-[1-(2-pyridyl)-4-piperidyl]ureido}ethyl)-9H-purine-2-carboxamide et à un procédé pour la préparation de, contenir de compositions et les usages d'une forme si cristalline.

 
Web www.patentalert.com

< Transfection agents

< Novel inhibitors of poxvirus replication

> Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof

> Chimeric Galpha 15 variants and their use in the analysis and discovery of modulators of G-protein coupled receptors

~ 00175